Loading...
NPI 1740570696 · Skokie, IL · General Practice Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Vladimir Urbin is a general practice physician provider located in Skokie, Illinois. This profile covers 25 Medicare and 25 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Vladimir Urbin |
| Address | 9631 Gross Point Rd Ste 107 |
| City | Skokie |
| State | IL |
| ZIP | 60076 |
| Taxonomy | General Practice Physician |
| NPI Enumerated | April 12, 2011 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $4.2M |
| Medicaid | $1.1M |
Provider payer mix is skewed toward Medicare in scale: Total Medicare revenue is $4.2M compared with Total Medicaid revenue of $1.1M, so Medicare is the dominant revenue source for this NPI. This difference implies contracting and utilization patterns will be driven primarily by Medicare-covered services and pricing.
Medicare revenue is highly concentrated in a small set of codes: the top 3 Medicare codes by revenue account for 82.5% of this provider's total Medicare revenue, led by Q4236 ($2.6M, 61.5%) and Q4234 ($691K, 16.5%). Both Q4236 and Q4234 are per-square-centimeter skin substitute add-on codes, which indicates skin-substitute products are the single largest Medicare revenue driver for this practice.
On Medicaid the revenue mix is less concentrated but still focused: the top 3 Medicaid codes by revenue account for 42.6% of Medicaid revenue, with 99233 ($204.9K, 17.9%), 91322 ($151.9K, 13.2%), and 90677 ($132K, 11.5%) as the leading contributors. This combination points to a mix of facility-based evaluation/management (99233) plus significant vaccine administration and pneumococcal vaccination activity under Medicaid.
Service-line footprint appears to be a blend of wound-care/skin-substitute procedures, facility-based E/M visits, and routine immunization services. The heavy Medicare billing for Q4236 and Q4234 signals wound-care or device-driven revenue, while repeated nursing facility and inpatient E/M codes (for example, Medicare 99307/99309 and Medicaid 99233/99223) show substantial activity in post-acute and facility settings.
Vaccination services represent a material ancillary revenue stream across both payers: Medicare shows 91322 at $190.9K (4.5%) and Medicare influenza/pneumococcal codes such as 90694 ($76.9K) and 90677 ($67.9K), while Medicaid lists 91322 at $151.9K (13.2%) and 90677 at $132K (11.5%). Several vaccine codes are high-volume relative to peers — for example, Medicare 90674 ranks #10 of 7360 (100th percentile; extreme outlier, far above typical national volume) and Medicaid 90694 ranks #1 of 15 (100th percentile; notably above typical state volume) — indicating the practice delivers vaccines at rates well above most peers.
Competitive standing is mixed by code and payer: for Medicare the two largest revenue codes for skin substitutes are moderate in national rank (Q4236 ranks #24 of 79, 71th percentile; Q4234 ranks #7 of 23, 73th percentile), so the practice is not a dominant national supplier of those products despite their local revenue importance. Conversely, the provider is a major in-state performer for many facility-based E/M codes under Medicaid — for example, Medicaid 99233 ranks #65 of 3828 (98th percentile; notably above typical state volume) and Medicaid 99307 ranks #9 of 542 (99th percentile; extreme outlier, far above typical state volume) — signaling strong local market presence in post-acute/facility care.
Tenure for this billing identity is long-standing: the NPI was enumerated on 2011-04-12 (~15 years ago), which supports treating observed patterns as established practice behavior rather than a transient billing artifact. This longevity reinforces that the mix of skin-substitute, facility-based E/M, and vaccine services is likely intentional and operationalized.
From a payer oversight and contracting perspective, the combination of extreme concentration in Q4236/Q4234 on Medicare and very high state-percentile volumes for facility E/M codes on Medicaid suggests two focal areas for review: unit pricing and utilization of skin-substitute add-ons (Q4236, Q4234) and frequency/setting of nursing-facility and subsequent inpatient visits (e.g., 99307, 99233). Given the provider’s mixed portfolio (device-driven wound care, facility-based E/M, and high-volume vaccination), payers should consider tailored contract terms or utilization management rules that address both high-cost product use and high-volume facility visits.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
25 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| Q4236 | Carepatch, per square centimeter (add-on, list separately in addition to primary procedure) | 2,690 | $960 | $2.6M |
| Q4234 | Xcellerate, per square centimeter (add-on, list separately in addition to primary procedure) | 1,150 | $600 | $691K |
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 1,340 | $140 | $190.9K |
| 99309 | The provider sees a patient for a subsequent nursing facility care visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making or the provider… | 1,370 | $90 | $120.5K |
| 90694 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is an inactivated, adjuvanted, preservative–free vaccine given as a 0.5 mL… | 1,010 | $80 | $76.9K |
| 90677 | This code represents a vaccine product administered intramuscularly to protect against pneumococcal disease, a bacterial infection. This is a 20–valent vaccine, protecting against 20 strains of the… | 240 | $280 | $67.9K |
| 99233 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 620 | $100 | $61.7K |
| 99306 | The provider sees a patient for an initial nursing facility care visit involving evaluation and management (E/M). The visit involves high medical decision making, and/or the provider spends at least… | 400 | $150 | $60.1K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 1,370 | $40 | $59K |
| 99307 | The provider sees a patient for a subsequent nursing facility care visit involving evaluation and management (E/M). The visit involves a straightforward level of medical decision making or the… | 1,820 | $30 | $58.2K |
Showing 1–10 of 25
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 25 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
25 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| Q4236 | 1 | 10 | 1,650 | $980 | $1.5M |
| Q4234 | 1 | 10 | 920 | $620 | $491.8K |
| 99309 | 67 | 1,400 | 180 | $80 | $29.5K |
| 99308 | 238 | 1,290 | 200 | $50 | $26.1K |
| 11043 | 27 | 60 | 40 | $160 | $21.3K |
| 91322 | 4 | 850 | 110 | $140 | $20.6K |
| 99233 | 350 | 5,990 | 100 | $100 | $18.7K |
| 91320 | 647 | 940 | 90 | $130 | $17.2K |
| 99310 | 141 | 620 | 70 | $110 | $15K |
| 99306 | 14 | 690 | 50 | $140 | $12.5K |
Showing 1–10 of 25
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
25 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99233 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 5,690 | $40 | $204.9K |
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 1,060 | $140 | $151.9K |
| 90677 | This code represents a vaccine product administered intramuscularly to protect against pneumococcal disease, a bacterial infection. This is a 20–valent vaccine, protecting against 20 strains of the… | 490 | $270 | $132K |
| 99223 | The provider sees a patient for an initial hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 1,680 | $70 | $115.6K |
| 99309 | The provider sees a patient for a subsequent nursing facility care visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making or the provider… | 4,040 | $30 | $109.1K |
| 99307 | The provider sees a patient for a subsequent nursing facility care visit involving evaluation and management (E/M). The visit involves a straightforward level of medical decision making or the… | 7,870 | $10 | $86.6K |
| 99308 | The provider sees a patient for a subsequent nursing facility care visit involving evaluation and management (E/M). The visit involves a low level of medical decision making and/or the provider… | 4,310 | $20 | $81.8K |
| 99306 | The provider sees a patient for an initial nursing facility care visit involving evaluation and management (E/M). The visit involves high medical decision making, and/or the provider spends at least… | 1,310 | $50 | $65.7K |
| 99232 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making or… | 2,160 | $20 | $47.5K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 870 | $40 | $32K |
Showing 1–10 of 25
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
25 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 11043 | The provider uses surgical instruments to remove the dead tissue in muscle and/or fascia, including any debridement of the epidermis, dermis, and subcutaneous tissue, for the first or only 20 cm2 or… | 24 | 30 | 200 | $90 | $63.6K |
| 99309 | The provider sees a patient for a subsequent nursing facility care visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making or the provider… | 111 | 1,540 | 410 | $20 | $30.2K |
| 99233 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 65 | 3,830 | 210 | $40 | $29.4K |
| 99232 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making or… | 556 | 4,800 | 210 | $30 | $29.3K |
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 4 | 50 | 20 | $120 | $27.8K |
| 99308 | The provider sees a patient for a subsequent nursing facility care visit involving evaluation and management (E/M). The visit involves a low level of medical decision making and/or the provider… | 146 | 1,590 | 360 | $10 | $23K |
| 91320 | This code represents a SARS–CoV–2 vaccine product (tris–sucrose formulation) administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 30 mcg/0.3 mL. | 52 | 60 | 50 | $100 | $18.2K |
| 99223 | The provider sees a patient for an initial hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 58 | 2,460 | 60 | $70 | $18.1K |
| 99231 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a straightforward or low level of medical… | 405 | 840 | 90 | $20 | $13.6K |
| 99310 | The provider sees a patient for a subsequent nursing facility care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the provider spends… | 167 | 540 | 100 | $30 | $12.9K |
Showing 1–10 of 25
Other providers in the same ZIP code as Vladimir Urbin, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.